Evidence map›Paper›PMID 24255811›Full record

ArticlePeerJ2013

Prolactin and fMRI response to SKF38393 in the baboon.

Brad Miller, Lauren A Marks, Jonathan M Koller, Blake J Newman, G Larry Bretthorst, Kevin J Black

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. The Role of fMRI in Drug Development: An Update.Advances in neurobiology · 2023
    Article
  3. Review
  4. The role of fMRI in drug development.Drug discovery today · 2018
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Brad MillerDepartment of Psychiatry, Washington University School of Medicine , St. Louis, MO , USA.
Lauren A Marks
Jonathan M Koller
Blake J Newman
G Larry Bretthorst
Kevin J Black
Washington University in St. Louis · US

Funding

SHORT-TERM TRAINING STUDENTS IN HEALTH PROFESSIONAL SCHOT35HL007815 · NHLBI · WASHINGTON UNIVERSITY · PI CHUNG, KOONG-NAH · 1995 to 2020
$2.8M
Training New Investigators in Neuroimaging and in the Neuropsychiatry of MovementK24MH087913 · NIMH · WASHINGTON UNIVERSITY · PI BLACK, KEVIN J · 2010 to 2014
$818k
QUANTITATIVE DOPAMINE RECEPTOR PHARMACODYNAMICS FROM FMRIR21MH081080 · NIMH · WASHINGTON UNIVERSITY · PI BLACK, KEVIN J · 2009 to 2010
$583k
NHLBI NIH HHS T35 HL007815NIMH NIH HHS K24 MH087913NIMH NIH HHS R21 MH081080
6 · The paper itself

Abstract

Background. This study's goal was to provide dose-response data for a dopamine agonist in the baboon using standard methods (replicate measurements at each dose, across a range of doses), as a standard against which to subsequently validate a novel pharmacological MRI (phMRI) method. Dependent variables were functional MRI (fMRI) data from brain regions selected a priori, and systemic prolactin release. Necessary first steps included estimating the magnitude and time course of prolactin response to anesthesia alone and to various doses of agonist. These first steps ("time course studies") were performed with three agonists, and the results were used to select promising agonists and to guide design details for the single-dose studies needed to generate dose-response curves. Methods. We studied 6 male baboons (Papio anubis) under low-dose isoflurane anesthesia after i.m. ketamine. Time course studies charted the changes in plasma prolactin levels over time after anesthesia alone or after an intravenous (i.v.) dose of the dopamine D 1-like agonists SKF82958 and SKF38393 or the D 2-like agonist pramipexole. In the single-dose dopamine agonist studies, one dose of SKF38393 (ranging from 0.0928-9.28 mg/kg, N = 5 animals) or pramipexole (0.00928-0.2 mg/kg, N = 1) was given i.v. during a 40-min blood oxygen level dependent (BOLD) fMRI session, to determine BOLD and plasma prolactin responses to different drug concentrations. BOLD response was quantified as the area under the time-signal curve for the first 15 min after the start of the drug infusion, compared to the linearly predicted signal from the baseline data before drug. The ED50 (estimated dose that produces 50% of the maximal possible response to drug) for SKF38393 was calculated for the serum prolactin response and for phMRI responses in hypothalamus, pituitary, striatum and midbrain. Results. Prolactin rose 2.4- to 12-fold with anesthesia alone, peaking around 50-90 min after ketamine administration and gradually tapering off but still remaining higher than baseline on isoflurane 3-5 h after ketamine. Baseline prolactin level increased with age. SKF82958 0.1 mg/kg i.v. produced no noticeable change in plasma prolactin concentration. SKF38393 produced a substantial increase in prolactin release that peaked at around 20-30 min and declined to pre-drug levels in about an hour. Pramipexole quickly reduced prolactin levels below baseline, reaching a nadir 2-3 h after infusion. SKF38393 produced clear, dose-responsive BOLD signal changes, and across the four regions, ED50 was estimated at 2.6-8.1 mg/kg. Conclusions. In the baboon, the dopamine D 1 receptor agonist SKF38393 produces clear plasma prolactin and phMRI dose-response curves. Variability in age and a modest sample size limit the precision of the conclusions.

Indexed as

Dopamine D1 receptor agonistsfMRIIsofluraneKetaminePapio anubisPharmacological fMRIPramipexoleProlactinSKF38393SKF82958

Identifiers

PMID24255811
PMCPMC3817584
OpenAlexW2158648176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.